An open label, three-way crossover study to evaluate the absolute bioavailability of two formulations of Wafermine Trademark, a novel sublingual wafer formulation of ketamine, in healthy volunteers under fasted conditions.

Trial Profile

An open label, three-way crossover study to evaluate the absolute bioavailability of two formulations of Wafermine Trademark, a novel sublingual wafer formulation of ketamine, in healthy volunteers under fasted conditions.

Completed
Phase of Trial: Phase I

Latest Information Update: 19 May 2017

At a glance

  • Drugs Ketamine (Primary) ; Ketamine
  • Indications Pain
  • Focus Pharmacokinetics
  • Sponsors iX Biopharma
  • Most Recent Events

    • 18 May 2017 Status changed from not yet recruiting to completed.
    • 28 Jan 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top